About

About Syntekabio USA Inc. Syntekabio, (226330.KQ), is a global artificial intelligence (AI) drug discovery platform pioneer, that has developed leading solutions for AI-powered small molecule discovery, antigenicity prediction as well as in-silico biologic therapeutic design. We offer customizable solutions for preclinical R&D across small molecule and antibody drugs and have developed our own internal pipeline of advanced pre-clinical assets (hits and leads) to key drug targets of interest. Our solutions address critical needs in automation and infrastructure necessary to develop and deploy AI-powered applications, thus allowing our clients to optimize their resources allocation to R&D activities. At BIO USA, we are excited to showcase our both our small molecule discovery platform, and our newly launched in-silico biologics discovery capabilities with 1) Neo-ARS, for cutting-edge neoantigen prediction, and 2) Ab-ARS for the prediction of novel complementarity-determining regions (CDRs) of antibody heavy chains. Syntekabio's mission and vision are to bring novel solutions to patients, faster via our fully automated AI-powered drug discovery and development services. Syntekabio, (226330.KQ), is a global artificial intelligence (AI) drug discovery platform pioneer, that has developed leading solutions for AI-powered small molecule discovery, antigenicity prediction as well as in-silico biologic therapeutic design. We offer customizable solutions for preclinical R&D across small molecule and antibody drugs and have developed our own internal pipeline of advanced pre-clinical assets (hits and leads) to key drug targets of interest. Our solutions address critical needs in automation and infrastructure necessary to develop and deploy AI-powered applications, thus allowing our clients to optimize their resources allocation to R&D activities. At BIO USA, we are excited to showcase our both our small molecule discovery platform, and our newly launched in-silico biologics discovery capabilities with 1) Neo-ARS, for cutting-edge neoantigen prediction, and 2) Ab-ARS for the prediction of novel complementarity-determining regions (CDRs) of antibody heavy chains. Syntekabio's mission and vision are to bring novel solutions to patients, faster via our fully automated AI-powered drug discovery and development services.